More recently, both the SUMMIT and ExteNET trials have shown the combination of neratinib, an irreversible pan-HER TKI, with endocrine therapies including fulvestrant and physicians’ choice of SERM/AI to have efficacy in HER2+/ER+ breast cancer patients [13,14]. Here, ERBB2 is linked to breast carcinoma.